Osteoporosis is more common after menopause. Approximately
two million osteoporotic fractures occur annually in the United States, which
create physical and psychological burdens for affected women by
diminishing their independence and quality of life.
A recent analysis of results from a randomized controlled clinical
trial indicates that Abaloparatide-SC, a novel therapy for osteoporosis,
provides consistent protection against bone fractures in postmenopausal
women with osteoporosis regardless of their baseline bone density, age,
and previous history of fracture.
‘Abaloparatide-SC provides consistent protection against bone fractures in postmenopausal women with osteoporosis regardless of their baseline bone density, age, and previous history of fracture.’
Investigators in the ACTIVE trial previously found that that the
drug reduces fractures and increases bone mineral density in
postmenopausal women with osteoporosis. This latest analysis, which is
published in the
Journal of Bone and Mineral Research (published
by the American Society for Bone and Mineral Research), evaluated
whether these benefits were consistent across different levels of
baseline risk.
"The landmark ACTIVE trial results show that abaloparatide-SC may
provide substantial benefit for a broad range of postmenopausal women
with osteoporosis," said lead author Dr. Felicia Cosman. "Anabolic therapy
could provide more consistent potent and early benefits to patients and
may be the most efficient way to achieve ultimate bone mineral density
goals."
Source: Eurekalert
Careers
